DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Unjha Formulations Ltd?

Unjha Formulations Ltd has a price-to-earnings (PE) ratio of 15.2 in the Healthcare sector.

What is the market capitalisation of Unjha Formulations Ltd?

Unjha Formulations Ltd has a market capitalisation of approximately ₹11 crore.

Unjha Formulations Ltd

531762·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

Mkt Cap₹11 Cr

P/E15.20

Vol—

Day—

52W18–28

Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

O—H—L—PC—VWAP—VOL—

52W₹17.52

₹27.89

Snapshot

Key stats

Mkt Cap

₹11 Cr

P/E

15.20Fair

P/B

2.79

ROE

20.10%Strong

ROCE

18.06%Efficient

52W High / Low

₹28 / ₹18

Div Yield

0.00%

EPS

₹0.92

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

15.2Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

20.1%Strong

Above 15% is considered healthy for Indian equities

ROCE

18.1%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹11 Cr

P/B

2.79

EPS

₹0.92

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+5.8%

+9.4%

10Y

+4.2%

Profit

+35.1%

+47.1%

10Y

+10.3%

EPS

+42.1%

+51.9%

10Y

+11.9%

Profile

Pros

Company is almost debt free.

Watch-outs

Cons

The company has delivered a poor sales growth of 9.60% over past five years.
Promoter holding is low: 36.9%

More Healthcare stocks · Pharmaceuticals

Explore Unjha Formulations Ltd’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.